Within the field of RNA therapeutics, antisense oligonucleotide-based therapeutics are a potentially powerful means of treating intractable diseases. However, if these therapeutics are used for the treatment of neurological disorders, safe yet efficient methods of delivering antisense oligonucleotides across the blood-brain barrier to the central nervous system must be developed. Here, we examined the use of angubindin-1, a binder to the tricellular tight junction, to modulate paracellular transport between brain microvascular endothelial cells in the blood-brain barrier for the delivery of antisense oligonucleotides to the central nervous system. This proof-ofconcept study demonstrated that intravenously injected angubindin-1 increased the permeability of the blood-brain barrier and enabled transient delivery of subsequently administered antisense oligonucleotides into the mouse brain and spinal cord, leading to silencing of a target RNA without any overt adverse effects. We also found that two bicellular tight junction modulators did not produce such a silencing effect, suggesting that the tricellular tight junction is likely a better target for the delivery of antisense oligonucleotides than the bicellular tight junction. Our delivery strategy of modulating the tricellular tight junction in the blood-brain barrier via angubindin-1 provides a novel avenue of research for the development of antisense oligonucleotide-based therapeutics for the treatment of neurological disorders.
Introduction
Antisense oligonucleotide (ASO)-based therapeutics are being intensively investigated as a promising means of treating intractable diseases because ASOs can target molecules such as mRNA and noncoding RNA, which cannot be targeted with existing drugs [1, 2] . The expectations for ASO-based drugs are particularly high for the treatment of neurological diseases for which there is currently no fundamental therapy. Nusinersen (Spinraza) is an ASO-based drug recently approved for the treatment of spinal muscular atrophy that is administered intrathecally [3] ; however, safer and more efficient means of delivering ASOs across the blood-brain barrier (BBB) to the central nervous system (CNS) via systemic administration are yet to be developed [4] .
The BBB is composed mainly of brain microvascular endothelial cells joined together by structures called tight junctions (TJs) that provide a barrier function and control the passage of substances to and from the circulating blood and the CNS [5] [6] [7] . Generally, only compounds with a molecular weight of < 450 Da are able to cross the BBB [5] . There are two types of TJ, bicellular TJs (bTJs) that form between two adjacent cells, and tricellular TJs (tTJs) that form at the point where three cells meet [8] . In bTJs in the BBB, claudin-5 provides the core barrier function of the TJ, and occludin and claudins-1, −3, and − 12 are also expressed despite these exact functions still needs to be clarified [9] . When claudin-5 is deficient, molecules as large as 800 Da can cross the BBB [10] .
Freeze-fracture replica electron microscopy revealed TJs as multiple sealing strands, and at tTJs, the apical-most TJ strands from neighboring cells meet and turn basally, forming a narrow channel called central tube [11, 12] . Tricellulin and angulins are two protein components known to localize at tTJs [13, 14] . Tricellulin, the first one to be identified by an investigation of epithelial cells [15] , forms a barrier to macromolecules (4-10 kDa) in tTJ [16] . Angulin has three subtypes: angulin-1 (originally known as lipolysis-stimulated lipoprotein receptor [LSR] ), angulin-2 (originally known as immunoglobulin-like domaincontaining receptor [ILDR] 1), and angulin-3 (originally known as ILDR2). In epithelial cells, these angulins complementarily contribute each other to the barrier function by recruiting tricellulin to the tTJ [17] . In the BBB, angulin-1 plays an important role to constitute the functional tTJ barrier in conjunction with tricellulin [13, 18] . Loss of angulin-1 results in embryonic lethality [19] . But if there is a technique to temporarily modulating the function of angulin-1 to increase the permeability of the tTJ, it may be possible to deliver ASOs, which have a molecular weight of several kilodaltons, across the BBB to the CNS.
Angubindin-1 is a novel binder to angulin-1 and -3 that was recently developed from Clostridium perfringens iota-toxin [20] . Iota-toxin is a binary toxin comprising an enzymatic component (Ia) and a receptorbinding component (Ib) [21] . The Ib domain contains 664 amino acids and is cytotoxic; however, a fragment of the domain corresponding to amino acids 421-664 (angubindin-1) modulates the tTJ without causing cytotoxicity and increases intestinal absorption of large molecules via the paracellular route by disrupting tricellulin recruitment [20, 22] . Since angulin-1-expressing vascular endothelial cells are localized at the BBB [23] , intravascular administration of angubindin-1 might allow the delivery of systemically administered ASOs to the CNS.
Here, we report a proof-of-concept study where intravenously administered angubindin-1 transiently enabled the delivery of an ASO across the mouse BBB to the CNS in vivo, based on the concept of modulating the tTJ in the BBB.
Materials and methods

Preparation of angubindin-1
The plasmid encoding angubindin-1 (pGEX-Ib421-664) was expressed as a fusion protein with glutathione S-transferase (GST) in Escherichia coli strain BL21 (DE3), as described previously [21] . After growth at 37°C and induction with isopropyl β-D-thiogalactopyranoside (Nacalai Tesque, Kyoto, Japan) of a 1000-mL culture, cells were harvested, resuspended in buffer F (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 2 mM CaCl 2 ), and then lysed by sonication. The lysates were applied to a glutathione sepharose 4B beads (GE Healthcare, Buckinghamshire, UK) and purified GST-tagged angubindin-1 was cleaved with thrombin. After the removal of thrombin by using Benzamidine Sepharose 4 Fast Flow (GE Healthcare), the solvent for angubindin-1 was changed to phosphate-buffered saline (PBS) by gel filtration using a PD-10 column (GE Healthcare), and the purified proteins were stored at −80°C until use. The concentration of the purified proteins was determined by using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA) with bovine serum albumin (BSA) as the standard. Purification of the recombinant proteins was confirmed by use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
To investigate the distribution of angubindin-1 in the brain, a DyLight 550 antibody labeling kit (Thermo Scientific) was used to label angubindin-1 with DyLight 550.
Preparation of C-CPE and C-CPEmt
The C-terminal fragment of C. perfringens enterotoxin (C-CPE) and its mutant form (C-CPEmt; C-CPE Y306W/S313H ), were prepared as described previously [24, 25] . Briefly, pET16b plasmids encoding C-CPE or C-CPEmt were transduced into E. coli strain BL21 (DE3), and production of the recombinant proteins was induced by the addition of isopropyl β-D-thiogalactopyranoside (Nacalai Tesque). Harvested cells were lysed in buffer A (10 mM Tris-HCl [pH 8.0], 400 mM NaCl, 5 mM MgCl 2 , 0.1 mM phenylmethanesulfonyl fluoride, 1 mM 2-mercaptoethanol, and 10% glycerol). The lysates were applied to a HiTrap Chelating HP column (GE Healthcare), and the recombinant proteins were eluted with buffer A containing imidazole. The buffer was exchanged with PBS by using a PD-10 column (GE Healthcare), and the purified protein was stored at −80°C until use. Purification of the recombinant proteins was confirmed by means of SDS-PAGE, followed by staining with Coomassie Brilliant Blue. The amount of protein was quantified by using a BCA protein assay kit in which BSA served as the standard (Thermo Scientific).
Preparation of C2II592-721
The plasmid encoding the receptor binding domain of Clostridium botulinum C2 toxin corresponding to amino acids 592-721 (pGEX-C2II592-721) was expressed as a fusion protein with GST in E. coli strain BL21 (DE3) as described previously [26] . After growth at 25°C and induction with isopropyl β-D-thiogalactopyranoside (Nacalai Tesque) of a 200-mL culture, cells were harvested, resuspended in buffer F, and then lysed by sonication. The lysates were applied to a glutathione sepharose 4B column (GE Healthcare), and purified GSTtagged C2II592-721 was eluted with elution buffer (10 mM reduced glutathione, pH 8.0, 50 mM Tris-HCl). After the purified GST-tagged C2II592-721 was cleaved with thrombin, the solvent for C2II592-721 was changed to PBS by gel filtration using a PD-10 column (GE Healthcare), and the purified proteins were stored at −80°C until use. The concentration of the purified protein was estimated by using a BCA protein assay kit (Pierce Chemical, Rockford, IL) with BSA as standard. Purification of the recombinant proteins was confirmed by use of SDS-PAGE, followed by staining with Coomassie Brilliant Blue.
In vitro BBB model study
An in vitro reconstituted rat BBB model comprising three cell types was purchased from PharmaCo-Cell Company Ltd., Nagasaki, Japan (RBT-24H) [27] . Monolayers of primary rat brain capillary endothelial cells and pericytes were cultured on the upper and lower side of the transwell filters, respectively, and primary rat astrocyte cultures were plated at the bottom of the 24-well culture dishes. Trans-endothelial electrical resistance (TEER) was measured over time in the media of the upper (apical, blood-side) and lower (basal, brain-side) compartments by using a TEER measurement system (Millicell ERS-2, Merck Millipore, Billerica, MA). According to manufacturer's instruction, the following assays were conducted after the TEER was confirmed to reach higher than 150 Ω·cm 2 . The culture medium was replaced with that containing or not containing a TJ modulator (Angubindin-1, C-CPE, or C-CPEmt), and after 24 h, the medium was replaced with the standard medium.
Relative TEER values were calculated by comparing the absolute values for the groups treated with a TJ modulator with those for the control group not treated with a TJ modulator. For immunocytochemistry, primary rat brain capillary endothelial cells were co-cultured with pericytes and astrocytes in culture slides. The cells were fixed in 4% paraformaldehyde for 30 min at room temperature and then stained with DAPI to visualize the nuclei and immunolabeled with anti-claudin-3 antibody (1:50, ab15102; Abcam, Cambridge, UK), followed by incubation with an Alexa Fluor 568-conjugated secondary antibody (1:200, A11011; Thermo Fisher Scientific). For RT-PCR, total RNA was extracted by using Isogen (Nippon Gene, Tokyo, Japan). The RNA (1000 ng) was treated with HLdsDNase (70800-202; ArcticZymes, Tromsø, Norway), and then was reverse transcribed with Transcriptor Universal cDNA Master (Roche Diagnostics, Mannheim, Germany). PCR reactions were performed by using PrimeSTAR Max DNA Polymerase (R045B, Takara Bio Inc., Shiga, Japan) with the primers for rat claudin-3 (forward: CTCTCATCGTGGT GTCTATCCTACT, reverse: TCAGACGTAGTCCTTACGGTCATAG), followed by an electrophoresis on 2% agarose gel.
Design and synthesis of oligonucleotides
The sequence of the 16-mer gapmer ASO designed to target mouse metastasis associated lung adenocarcinoma transcript-1 (malat-1) RNA (NR_002847) was 5′-C*T*A*g*t*t*c*a*c*t*g*a*a*T*G*C-3′, where lowercase letters represent DNA, uppercase letters represent locked nucleic acid (LNA) (capital C denotes LNA methylcytosine), and asterisks represent phosphorothioate linkages. For immunohistochemical examinations, Alexa Fluor 647 was covalently bound to the 5′-end of the ASO. The ASO was synthesized by Gene Design (Osaka, Japan).
Mouse studies
Wild-type female C57BL/6 mice aged 8 to 11 weeks (Oriental Yeast, Tokyo, Japan) were kept on a 12-h light/dark cycle in a pathogen-free animal facility with free access to food and water. The ASO was administered to the mice by tail vein injection at doses chosen in accordance with each animal's body weight. All oligonucleotides were formulated in PBS, which was also used as the control. For postmortem analyses, mice were deeply anesthetized with intraperitoneally administered pentobarbital (60 mg/kg) and then killed by transcardiac perfusion with PBS after confirming absence of the blink reflex.
Animal experiments were performed at Tokyo Medical and Dental University (TMDU). At least three mice per experiment were used. All experimental protocols were approved by the Institutional Animal Care and Use Committee of TMDU. The procedures were in accordance with the ethical and safety guidelines for animal experiments at TMDU.
Immunohistochemical analyses
After mice were euthanized, the brains were collected and fixed in 4% paraformaldehyde/PBS for 12 h, snap-frozen in liquid nitrogen, and sectioned (thickness, 14 μm) by using a Leica CM3050 S cryostat (Leica Microsystems, Wetzlar, Germany). The sections were stained with 4′,6-diamidino-2-phenylindole (DAPI) to visualize the nuclei; immunolabeled with antibodies against CD31 (1:200, sc-18,916; Santa Cruz Biotechnology, Dallas, TX), Tuj1 (1:200, 801,201; BioLegend, San Diego, CA), Iba1 (1:200, 019-19,741; Wako Pure Chemical Industries, Ltd., Osaka, Japan), and glial fibrillary acidic protein (1:200, ab16997; Abcam) to visualize vascular endothelial cells, neurons, microglia, and astrocytes, respectively; and then incubated with an Alexa Fluor 488-conjugated secondary antibody (1:100, A11001, A11006, or A11008; Thermo Fisher Scientific). To visualize angulin-1, sections were immunolabeled with antibody against angulin-1 (1:200, HPA007270; Sigma-Aldrich, St. Louis, MO), followed by incubation with an Alexa Fluor 568-conjugated secondary antibody (1:200, A11011; Thermo Fisher Scientific). All images were acquired with an A1R confocal laser scanning microscope (Nikon, Tokyo, Japan).
Quantitative reverse transcription-polymerase chain reaction
Total RNA was extracted from mouse brain by using Isogen (Nippon Gene). The RNA (500 ng) was reverse transcribed with Transcriptor Universal cDNA Master (Roche Diagnostics) or PrimeScript RT Master Mix (Takara Bio Inc.). To detect short oligonucleotides, including the ASO strand, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis was performed by using a TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher Scientific) and a Light Cycler 480 Real-Time PCR Instrument (Roche Diagnostics). The primers and probes for mouse malat-1 (Mm01227912_s1), glyceraldehyde-3-phosphate dehydrogenase (gapdh; 4352932E), U6 (001973), interferon-β1 (Mm00439546_s1), interferon-γ (Mm00801778_m1), tumor necrosis factor-α (Mm00443258_m1), and the ASO strand were designed by Thermo Fisher Scientific. Relative malat-1 RNA levels and relative ASO amounts were calculated in comparison with gapdh mRNA levels and U6 RNA levels, respectively, which were used as internal controls.
Evaluation of adverse effects
Blood samples were collected from the mice for serum chemistry analyses, and livers and brains were collected for pathological studies; livers and brains were stained with hematoxylin and eosin (Muto Pure Chemicals, Tokyo, Japan).
To examine whether the BBB was disrupted, mice were intravenously injected with angubindin-1 at 10 mg/kg or the same amount (in moles) of a bTJ modulator (C-CPE or C-CPEmt), and 1 h later were injected with 80 μL of 2% Evans blue solution. After 24 h, the brains were obtained and examined macroscopically.
Statistical analysis
All data are presented as mean ± s.e.m. Student's two-tailed t-test with Bonferroni-Holm adjustment was used to determine the significance of differences between two groups of results obtained from the qRT-PCR assays.
Results
Preparation of angubindin-1 and its effect on an in vitro BBB model
We prepared recombinant GST-fused angubindin-1 by using an E. coli expression system, as previously described [20] . After GST digestion and purification, we confirmed via a gel-shift assay that the obtained angubindin-1 had a putative molecular weight of 28 kDa (Supplementary Fig. S1 ). We also prepared recombinant protein fragments of two bTJ modulators from another toxin produced by the same bacterium: C-CPE, which binds claudin-3 and -4 [28] and C-CPEmt that binds claudin-5 [29] . Both bTJ modulators were confirmed to have a molecular weight of 16.9 kDa (Supplementary Fig. S1 ).
We next investigated whether the TJ modulators could modulate the barrier function of the BBB in vitro. We used an established BBB model in which primary brain capillary endothelial cells were co-cultured with brain pericytes and astrocytes in transwell system, and we measured TEER over time, which is a widely recognized indicator of BBB integrity [30, 31] . Treatment of the endothelial cells with angubindin-1 decreased TEER in a dose-dependent manner to a minimum of 9.3% (200 μg/mL angubindin-1) of control (no angubindin-1), and removal of angubindin-1 led to the recovery of TEER almost to the original level within 96 h (Fig. 1A, Supplementary Fig. S2A ). Treatment of the cells with the bTJ modulators (C-CPE or C-CPEmt) at 120 μg/mL (same molar concentration as 200 μg/mL of angubindin-1) decreased TEER to a minimum of 2.6% and 2.9% of control, respectively, followed by a gradual recovery after washout (Fig. 1B, Supplementary Fig. S2B ). It should be noted that claudin-5 (the binding target of C-CPEmt) was previously confirmed to work at the cells of this in vitro BBB model [28] and that we verified the expression of claudin-3 (the binding target of C-CPE) in these cells by immunocytochemical and RT-PCR analyses ( Supplementary Fig. S3 ). These data indicate that all three TJ modulators reversibly decreased the integrity of the BBB in vitro.
Effects of intravenously injected angubindin-1 on angulin-1 in mouse brain
To examine the distribution of intravenously administered angubindin-1, we injected DyLight 550-labeled angubindin-1 formulated in PBS into the tail vein of mice and examined its localization in the brain at 1 h after injection. Observation by confocal laser scanning microscopy revealed dotted fluorescent signals of angubindin-1 along the brain microvasculature endothelium visualized with an anti-CD31 antibody ( Fig. 2A) . These signals of angubindin-1 were colocalized with those of angulin-1, suggesting the localization of tTJs ( Fig. 2A) [18] . A similar signal distribution was seen in all parts of the brain, and almost no fluorescent signals were detected in other types of brain cell such as in neurons or glia, indicating that intravenously administered angubindin-1 was likely to specifically attach to angulin-1 at tTJs in the brain microvascular endothelium.
A previous study in vitro demonstrated that angubindin-1 treatment led to removal of angulin-1 probably by a lateral diffusion from tTJs to bTJs and enhanced the permeation of macromolecular solutes [20] . Then we investigated the localization of angulin-1 at the brain microvascular endothelium over time before and after intravenous administration of angubindin-1. Confocal laser scanning images revealed dotted signals of angulin-1 before and 1 h after an injection of angubindin-1 (Fig. 2B) . At 2 h and 4 h after an injection of angubindin-1, however, angulin-1 was not detected (Fig. 2B) , possibly due to the lateral diffusion from tTJs to bTJs. We found again dotted signals of angulin-1 24 h after an injection of angubindin-1 (Fig. 2B) , suggesting that the effects of angubindin-1 on angulin-1 at the BBB are transient. Moreover, we also conducted an experiment using a protein fragment which does not bind to angulin-1. Specifically, we used the binding domain of Clostridium botulinum C2 toxin corresponding to amino acids residues 592 to 721 (C2II592-721), which was previously used as a negative control of angubindin-1 [20] . At 2 h after an injection of C2II592-721 (the same amount as angubindin-1 in moles), we observed dotted signals of angulin-1 at brain microvascular endothelium as in the case before an injection of angubindin-1 (Fig. 2B) . Taken together, intravenously administered angubindin-1 is considered to reversibly remove angulin-1 from tTJ at the BBB in vivo.
Effects of TJ modulators on the distribution of ASO in mouse brain
We selected mouse malat-1, a long non-coding RNA highly and ubiquitously expressed in the nucleus, as the target RNA because lack of malat-1 expression does not cause a pathologic phenotype or affect global gene expression in mice [32] . The sequence of a malat-1-targeting ASO that in previous studies demonstrated high silencing efficacy in many tissues and cell types after systemic administration [33] was adopted, although the chemical modifications were different because of the commercial availability in Japan, that is, our ASO had a gapmer structure of 10 DNA nucleotides flanked by three LNA nucleotides, whereas the ASOs used in previous studies had 2′-O-methoxy ethyl or constrained ethyl bicyclic nucleic acid gapmer structures [32, 33] . All internucleotide linkages were modified by phosphorothioate substitution to increase the stability of the ASO in plasma and its binding to plasma proteins and thus tissue bioavailability [34] .
To verify the effects of TJ modulators on the distribution of the ASO in mouse brain, we first intravenously injected mice with 10 mg/kg angubindin-1 or the same amount (in moles) of bTJ modulator (C-CPE or C-CPEmt), followed 1 h later by intravenous injection of 50 mg/kg Alexa Fluor 647-labeled ASO. The serum concentration in mice after intravenous injection of 10 mg/kg angubindin-1 was approximately 200 μg/mL, which was equivalent to the concentration in the study in vitro. After a further 1 h, we examined the distribution of ASO in the brain. The fluorescent signals of the ASO were not apparent in any region of the brain when the ASO was injected without prior administration of a TJ modulator ("ASO only") or after prior administration of either of the bTJ modulators (Fig. 3A) . However, prior administration of angubindin-1 resulted in many ASO signals in neurons, which were visualized with Tuj1 antibody (Fig. 3A) . ASO was not observed in astrocytes, which were marked with an anti-glial fibrillary acidic protein antibody, regardless of the TJ modulator. A similar signal distribution was observed in the spinal cord when the ASO was administered after angubindin-1 but not after either of the bTJ modulators (Supplementary Fig. S4 ). These results suggest that of the TJ modulators tested, only angubindin-1 enabled delivery of ASO to the CNS.
Next, we analyzed the amount of intravenously administered ASO that was distributed to the brain after intravenous injection of a TJ modulator. Mice were first intravenously injected with angubindin-1 or one of the bTJ modulators followed 1 h later by intravenous injection with ASO; the mice were then euthanized after a further 72 h. Quantitative reverse-transcription PCR was used to quantify the ASO strands in RNA samples extracted from brain homogenates. Accumulation of ASO in the brain was markedly higher in mice injected with angubidin-1 than in mice injected with and without a bTJ modulator (Fig. 3B) . These results are consistent with the observed accumulation of fluorescently labeled ASO in the brain (Fig. 3A) .
Silencing effect of ASO in mouse brain
To examine the silencing effect of the ASO, we intravenously injected the mice with 10 mg/kg angubindin-1 or the same amount (in moles) of bTJ modulator (C-CPE or C-CPEmt) followed 1 h later by intravenous injection of 50 mg/kg ASO. After a further 72 h, the mice were euthanized. Quantitative reverse-transcription PCR was used to determine the malat-1 RNA levels in the homogenates of liver, brain, and spinal cord. In all mice, irrespective of whether they were administered a TJ modulator, malat-1 RNA expression was reduced by > 90% in the liver, a main destination of systemically administered ASO [35] , suggesting that the TJ modulators did not markedly influence accumulation of ASO in the liver. Administration of ASO without prior administration of a TJ modulator ("ASO only") showed only a slight silencing effect (10%-20% of control) in the CNS; however, prior administration of angubindin-1 produced a silencing effect of 30% to 40% of control (Fig. 4) . Neither of the two bTJ modulators increased the silencing effect of ASO in any region of the CNS examined (Fig. 4) . Thus, only angubindin-1 boosted the silencing effect of ASO in the brain and spinal cord.
Next, we examined the effects of various doses of angubindin-1 with the same injection protocol used in the previous experiment. The silencing effect of ASO was increased in a dose-dependent manner up to a dose of 3 mg/kg, after which the silencing effect remained constant (Fig. 5A) , suggesting a maximum effect in the brain and spinal cord was reached at a dose of 3 mg/kg. In the mice injected with up to 1 mg/kg angubindin-1, the silencing effect of ASO tended to be better in the brain compared to the cervical and lumbar spinal cord (Fig. 5A) . This difference in effect within the CNS may have resulted from brain-specific presence of circumventricular organs that are devoid of the BBB and are in contact with blood stream [33] .
We also examined how long angubindin-1 increased the silencing effect of the ASO in the CNS. We intravenously injected mice with 10 mg/kg angubindin-1, followed 1 to 24 h later with intravenous injection of 50 mg/kg ASO. The silencing effect of ASO, assessed after 72 h, was highest at dosing intervals of 2 and 4 h (approximately 40%) in all regions of the CNS examined (Fig. 5B) , suggesting that angubindin-1 transiently enhanced delivery of ASO to the brain and spinal cord.
Finally, we examined the effect of dose on the silencing effect of the ASO. We intravenously administered mice with 10 mg/kg angubindin-1 followed 2 h later (based on the previous result showing the greatest effects) with various doses of ASO. The silencing effect of ASO in the brain and spinal cord increased in a dose-dependent manner (Fig. 5C) .
Together, these data indicate that both angubindin-1 and ASO have dose-dependent effects, and that there is an optimal dosing interval.
Adverse effects
We evaluated the potential adverse effects of the TJ modulators by intravenously injecting the mice with 10 mg/kg angubindin-1 or the same amount (in moles) of bTJ modulator (C-CPE or C-CPEmt), followed 1 h later with intravenous injection of 50 mg/kg ASO. After a further 72 h, the mice were euthanized. Mice receiving a TJ modulator appeared healthy throughout the experiment, and there were no remarkable findings at autopsy. In all mice, hematoxylin and eosin staining of liver and brain tissue revealed no abnormalities ( Supplementary Fig. S5 ), and analysis of serum chemistry showed no liver or kidney dysfunction (Supplementary Table S1 ). Expression of pro-inflammatory cytokine RNA for interferon-β1, interferon-γ, and tumor necrosis factor-α in liver was not detected by qRT-PCR, suggesting no overt immunostimulatory effects were induced.
Finally, we conducted a common screening assessment using Evans blue to investigate whether the barrier function of the BBB was disrupted by the TJ modulators. Intravenously administered Evans blue (961 Da) has high affinity to serum albumin (66 kDa) and circulates in the blood stream largely as a macromolecule, which does not pass the BBB under normal physiological condition but accumulates in the brain when the BBB is disrupted [36, 37] . Mice were intravenously injected with 10 mg/kg angubindin-1 or the same amount (in moles) of bTJ modulator (C-CPE or C-CPEmt), followed 1 h later with intravenous injection of 2% Evans blue solution. After a further 24 h, the brains were examined. None of the mice showed massive extravasation of Evans blue into the brain (Supplementary Fig. S6 ), suggesting that the barrier function of BBB was not completely disrupted in the mice injected with a TJ modulator. Thus, these results indicate that the TJ modulators did not cause any overt adverse effects in vivo.
Discussion
ASOs exert their gene-silencing effects through different mechanisms of action, making them amenable to a variety of molecular targets and disease processes [34] . Recent progress in ASO-based technology has been largely due to chemical modifications and improvements made to the ASO structure; our gapmer ASO structure was composed of DNA nucleotides flanked by LNA nucleotides, with all internucleotide linkages modified by phosphorothioate substitution, which is a structure commonly used in preclinical and clinical contexts [4, 34] . Despite being large, highly charged molecules, ASOs distribute widely throughout the CNS when administered to the cerebrospinal fluid, and this characteristic has greatly aided the application of ASOs for the treatment of CNS disorders [4] . The most pivotal achievement to date is nusinersen, a recently approved ASO-based drug specifically designed to alter splicing of survival motor neuron-2 pre-mRNA and thus increase the amount of functional survival motor neuron protein, which is deficient in patients with spinal muscular atrophy, achieving significantly favorable results upon intrathecal administration [3] . In addition, ongoing clinical trials are examining the use of ASO-based therapies for the treatment of amyotrophic lateral sclerosis caused by mutations within the Cu/Zn superoxide dismutase 1 gene, and of Huntington's disease caused by abnormal expansion of a CAG repeat in the huntingtin gene, with both therapies being administered intrathecally [4] . However, given the low invasiveness and relative simplicity and safety of systemic administration, which is currently used for the administration of mipomersen (Kynamro) for the treatment familial was intravenously injected to mice followed 1 h later by intravenous injection of 50 mg/kg Alexa Fluor 647-labeled antisense oligonucleotide (ASO). No TJ modulator was administered to the "ASO only" mice. After a further 1 h, brains were collected, and sections were stained with DAPI and immunolabeled with antibody against Tuj1. Red, Alexa Fluor 647. Scale bars = 10 μm. (B) Angubindin-1 (10 mg/kg) or the same amount (in moles) of a bTJ modulator (C-CPE or C-CPEmt) was intravenously injected to mice followed 1 h later by intravenous injection of 50 mg/ kg ASO. The amount of ASO in the brain was measured by quantitative RT-PCR after a further 72 h. Data shown are relative to mouse U6 RNA levels and are expressed as mean ± s.e.m. (N = 4, **P < 0.01). P values were calculated by using Student's two-tailed t-test with Bonferroni-Holm adjustment. Fig. 4 . Effects of tight junction modulators on the silencing effect of antisense oligonucleotide in mouse brain. Angubindin-1 (10 mg/kg) or the same amount (in moles) of a bicellular tight junction (bTJ) modulator (C-terminal fragment of Clostridium perfringens enterotoxin [C-CPE] or its mutant form [C-CPEmt]) was intravenously injected to mice, followed 1 h later by intravenous injection of 50 mg/kg antisense oligonucleotide (ASO). No TJ modulator was administered to the "ASO only" mice, and no ASO was administered to the "Angubindin-1 only" mice. Malat-1 RNA levels were measured in the homogenates of brain and spinal cord after a further 72 h by quantitative RT-PCR. Data shown are relative to gapdh mRNA levels and are expressed as mean ± s.e.m. (N = 4, *P < 0.05 versus Control). P values were calculated by using Student's two-tailed t-test with Bonferroni-Holm adjustment.
hypercholesterolemia [38] and eteplirsen (Exondys 51) for the treatment of Duchenne muscular atrophy [39] , it would be advantageous to use this mode of administration also for the treatment of CNS disorders.
Various strategies have been developed to deliver ASOs across the BBB to the CNS. A common strategy is to utilize receptor-mediated transcytosis, which allows macromolecules such as transferrin, insulin, leptin, and insulin-like growth factor 1 to cross the BBB. For example, a monoclonal antibody to transferrin receptor has been conjugated as a delivery ligand directly to ASO [40] and to nanoparticles carrying ASO [41] , but no products utilizing receptor-mediated transcytosis have proceeded to clinical development. Tagging cell-penetrating peptides with ASO might also be possible because of the peptides' strong transmembrane capacity [42] , but adverse effects such as lethargy, weight loss, and renal dysfunction are yet to be overcome [43] . The strategy of specifically modulating tTJs in the BBB, the molecular properties of which we have only recently begun to be understood in more detail [18] , has not yet been thoroughly tested.
TJs are no longer regarded as simple barriers between different compartments of the body, but as multifunctional molecular gates that control paracellular transport of ions and molecules via two functionally distinct pathways: the charge-selective pore pathway and the sizeselective leak pathway [8, 31] . The charge-selective pathway utilizes pore-like structures formed from intercellular claudin complexes and allows the passage of small ions and molecules [8, 31] . In contrast, the size-selective pathway allows transient and stepwise leakage of larger molecules, possibly via serial dissociation and reformation of TJ strands in the apical to basolateral direction [8] . C-CPE and C-CPEmt, which bind to claudin species, did not achieve an efficient ASO delivery into the CNS and thus, these TJ modulators might not modulate the sizeselective leak pathway but mainly affect the charge-selective pore pathway at the endothelial cells of the BBB. Since C-CPE was reported to induce the leakage of macromolecules at the epithelial cells [29, 44] , there may be some differences in the mechanism of action in C-CPE between endothelial and epithelial cells. Angulin-1 contributes to the constitution of TJ strands at tricellular contact points by recruiting tricellulin and to the consequential formation of a central tube in the extracellular space [17] , and tricellulin forms a barrier to macromolecules in tTJs without affecting ion permeability [16] . Given that Fig. 5 . Effects of angubindin-1 on the silencing effect of antisense oligonucleotide in mouse brain. (A) Angubindin-1 was intravenously administered to mice at different doses followed 1 h later by intravenous injection of 50 mg/kg antisense oligonucleotide (ASO). (B) Angubindin-1 (10 mg/kg) was intravenously administered to mice followed by intravenous injection of 50 mg/kg ASO at different time periods. (C) Angubindin-1 (10 mg/kg) was intravenously administered followed 2 h later by intravenous injection of ASO at different doses. (A)-(C) Malat-1 RNA levels in the homogenates of brain and spinal cord were measured by quantitative RT-PCR after a further 72 h. Data shown are relative to gapdh mRNA levels and are expressed as mean ± s.e.m. (N = 3, *P < 0.05, **P < 0.01 versus Control). P values were calculated by using Student's two-tailed t-test with Bonferroni-Holm adjustment.
the central tube in TJs is likely wide enough for the passage of macromolecules (4-10 kDa) but too rare enough to contribute significantly to ion permeability [16] , angubindin-1 likely specifically modulates the size-selective pathway. Thus, modulating tTJs via angubindin-1 might be a good way to allow ASOs to cross the BBB through this size-selective pathway. However, we should note that there is a possibility that the action of angudindin-1 to the BBB may not be anbulin-1-specific since we have not conducted negative control experiments using angubindin-1 mutant which does not bind to angulin-1.
The effects of bTJ and tTJ modulators can also be discussed by comparing the results of in vitro and in vivo studies. TEER decreases with increased permeability of either the charge-selective pore pathway or the size-selective leak pathway [31] . It should be noted that the decrease in TEER induced by administration of 200 μg/mL angubindin-1, which was equivalent to the serum concentration in mice after intravenous injection of 10 mg/kg angubindin-1, was less than that induced by C-CPE or C-CPEmt at the same concentration in moles (Fig. 1) . Moreover, TEER recovered quicker in cells treated with angubindin-1 compared with in those treated with C-CPE or C-CPEmt (Fig. 1) . These results are similar to those obtained in a previously reported study using Caco-2 cells, an established cell line derived from epithelial colorectal adenocarcinoma [20] . Thus, although the activities of C-CPE and C-CPEmt measured using TEER were stronger than that of angubindin-1 in vitro, only angubindin-1 promoted the delivery of the ASO to the CNS in vivo, suggesting that angubindin-1 might almost specifically opens the tTJs of the BBB. On the other hand, a considerably decreased absolute TEER value after treating with angubindin-1 especially at high concentrations might be caused by influences of angulin-1 on the barrier function not only of tTJs but also of bTJs in our in vitro BBB model. Although the cell type was different, the decrease of TEER value after treating with 200 μg/mL angubindin-1 seemed to be bigger than that of trans-epithelial electric resistance observed in angulin-1-knockdown epithelial cells [17, 44] . For future application of angubindin-1 in opening the BBB, its mechanism of action on the BBB will need to be elucidated in detail.
It will also be necessary to carefully verify the safety of tTJ-modulating strategies using angubindin-1. In the present study, we found that although the ASO (molecular weight, 5.3 kDa) was able to enter the CNS, Evans blue bound to albumin (approximately 67 kDa) was not. This leaves a large molecular size range within which the molecular weight cutoff for entry into the CNS could lie. Therefore, at present, the possibility of nonspecific substance entry is the biggest limitation to the strategy of using angubindin-1 to modulate tTJs, and further examination of the molecular weight cutoff is warranted. To further understand other potential adverse effects, it will also be important to elucidate in detail the influence of intravenously administered angubindin-1 on molecular expression in the brain.
Moreover, it would be important to discuss how intravenously administered angubindin-1 changes the biodistribution of subsequently administered ASO by binding to angulin-1 and -3. Outside the brain, angulin-1 is expressed in liver, stomach, small intestine, colon, kidney, gall bladder, lung, skin, epididymis, salivary gland, nasal mucosa, and inner ear, and angulin-3 is expressed in stomach, kidney, peripheral nerve, and eye [17] . Since these angulin molecules are mostly localized at epithelial cells which do not face to the blood stream, angubindin-1 is not likely to change the biodistribution of ASO in the above organs or tissues drastically. In fact, the ASO-mediated reduction of malat-1 RNA levels was not altered by angubindin-1 even in the liver where ASO is considered to easily approach to the parenchymal cells via discontinuous capillary vessels called sinusoids. When confined to vascular endothelial cells directly in contact with blood stream, angulin-1 is reported to be present in the inner blood-retinal barrier in addition to the BBB [23] , suggesting that angubindin-1 may also achieve efficient delivery of ASO into the retina.
To consider the therapeutic application of our technology, clarifying the ASO distribution within the brain after passing through the BBB will be important; the target molecule of ASO should be expressed at the cells into which ASO can be delivered. We did not observe the ASO uptake into astrocytes, but we can not determine that ASO would not be delivered to astrocytes at all because the immunohistochemistry of glial fibrillary acidic protein would not provide the entire picture of astrocytes which have countless fine protrusions. Given that an intracerebroventricular infusion of ASO to bypass the BBB led to suppress a target molecule of astrocytes [45] , it is rather likely that the ASO passing through the BBB and entering the CNS might partially reach astrocytes. Malat-1 RNA is ubiquitously expressed and therefore, the silencing effects of malat-1-targeting ASO in our examinations are the sum total of the effect at every cell in the CNS, including neuronal and glial cells. The heterogeneity of cellular distribution of ASO within the CNS should be further investigated, for example by quantifying ASO after fractionation of each cellular component.
Conclusion
Here, we efficiently silenced a target RNA in the mouse CNS by intravenous sequential administration of angubindin-1 followed by an ASO. Angubindin-1 reversibly decreased BBB integrity in vitro and was likely to specifically localize at tTJs in brain microvascular endothelium upon intravenous administration in vivo. The delivery of subsequently administered ASO to the brain was verified, and silencing of the target RNA in the CNS was shown to be dependent on the dosage of angubindin-1 and ASO, as well as the interval of administration between them. There were no overt adverse effects induced by angubindin-1 in vivo. We believe that our novel strategy of modulating the tTJ in the BBB will open a new line of research in the field of RNA therapeutics for the treatment of intractable neurological disorders.
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